Pyxis Oncology Q3 net loss $27.7M, expands Pfizer ADC licensing deal

Pyxis Oncology, Inc.

2022-Q3 EPS reported -$2.61

Net loss of $27.7M ($0.85 per share) for Q3 2022 vs. $14.2M ($8.96 per share) in Q3 2021.
Cash and cash equivalents (incl. restricted) $200.0M as of Sept 30, 2022; expected to fund operations into end of 2024.
Expanded worldwide licensing deal with Pfizer for exclusive rights to Pfizer’s ADC technology platform and toolkit.
First multi-target sublicensing agreement executed with a stealth ADC company under the new Pfizer arrangement.
IND filings for PYX-106 and PYX-201 on track by end of 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pyxis Oncology, Inc. reported three months ended September 30, 2022 results: net income $27.7 million, EPS $(0.85) per common share.

Period: three months ended September 30, 2022
Net income: $27.7 million
EPS: $(0.85) per common share
Result: reported results

Exact text from the filing

Net loss was $27.7 million, or $(0.85) per common share, for the three months ended September 30, 2022

View on SEC.gov

Browse all earnings releases →

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-020699

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.